Merck still on the hunt for billion-dollar deals, citing Prometheus and Daiichi Sankyo as examples

Mer­ck is still in pur­suit of deals of a sim­i­lar size and scope to the com­pa­ny’s ac­qui­si­tions of Prometheus Bio­sciences and Ac­celeron, and is will­ing to pay up to $15 bil­lion.

It’s al­so still con­sid­er­ing small­er deals and col­lab­o­ra­tions.

Dur­ing Thurs­day’s fourth-quar­ter earn­ings call, Mer­ck CEO Rob Davis out­lined his views on the drug­mak­er’s port­fo­lio, say­ing he feels good about its progress but he con­tin­ues to “be­lieve we need more.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.